ACAD— ACADIA PHARMACEUTICALS INC

MaterialsBiotechnology$5.1B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total revenues	$1.07B+11.9%	$957.8M+31.8%	$726.4M+40.4%	$517.2M
Cost of product sales	$89.0M+8.7%	$81.8M+96.6%	$41.6M+309.6%	$10.2M
Research and development	$328.8M+8.4%	$303.2M-13.8%	$351.6M-2.8%	$361.6M
Selling, general and administrative	$548.9M+12.4%	$488.4M+20.1%	$406.6M+10.2%	$369.1M
Gain on sale of non-financial asset	$0+100.0%	-$146.5M	—	—
Total operating expenses	$966.7M+33.0%	$727.0M-9.1%	$799.8M+8.0%	$740.8M
Income (loss) from operations	$104.8M-54.6%	$230.8M+414.5%	-$73.4M+67.2%	-$223.6M
Interest income, net	$31.7M+24.6%	$25.5M+47.7%	$17.2M+160.7%	$6.6M
Other income	$2.4M+30.1%	$1.8M-64.3%	$5.1M+44.2%	$3.5M
Income (loss) before income taxes	$138.9M-46.2%	$258.1M+605.7%	-$51.0M+76.1%	-$213.4M
Income tax (benefit) expense	-$252.1M-897.2%	$31.6M+208.5%	$10.3M+305.0%	$2.5M
Consolidated net income	$391.0M+72.7%	$226.5M+469.5%	-$61.3M+71.6%	-$216.0M
Earnings (net loss) per share, Basic	$2320.00+69.3%	$1370.00+470.3%	-$370.00+72.4%	-$1340.00
Earnings (net loss) per share, diluted	$2300.00+69.1%	$1360.00+467.6%	-$370.00+72.4%	-$1340.00
Weighted average common shares outstanding, basic	168.4M+1.6%	165.7M+1.2%	163.8M+1.3%	161.7M
Weighted average common shares outstanding, diluted	169.9M+2.1%	166.4M+1.6%	163.8M+1.3%	161.7M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.